Article information
Full text is only aviable in PDF
References
[1.]
N. Schlesinger, H.R. Schumacher.
Gout: How much of what we do is evidence based?.
Evidence-based rheumatology, pp. 65-95
[2.]
F. Perez-Ruiz, M. Calabozo, M.J. Fernandez-Lopez, A.M. Herrero-Beites, E. Ruiz-Lucea, G. Garcia-Erauskin, et al.
Treatment of chronic gout in patients with renal function impairment. An open, randomized, actively controlled.
J Clin Rheumatol, 5 (1999), pp. 49-55
[3.]
F. Perez-Ruiz, A. Alonso-Ruiz, M. Calabozo, A. Herrero-Beites, G. Garcia-Erauskin, E. Ruiz-Lucea.
Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
Ann Rheum Dis, 57 (1998), pp. 545-549
[4.]
K.P.H. Pritzker.
Crystal deposition in joints: prevalence and relevance for arthritis.
J Rheumatol, 35 (2008), pp. 1008-1009
[5.]
E. Loza Santamaria.
Epidemiología de la gota.
Reumatol Clin., 10 (2010), pp. 2-6
[6.]
R. Terkeltaub, D.A. Bushinsky, M.A. Becker.
Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics.
Arthritis Res Ther, 8 (2006), pp. S4
[7.]
F. Liote.
Nguyen CEH-K. Fisiopatología de la inflamación en la gota.
Reumatol Clin, 10 (2010), pp. 7-12
[8.]
W. Zhang, M. Doherty, E. Pascual, T.B.V. Bardin, P. Conagham, J. Gerster, et al.
EULAR evidence based recommendations for gout Part I. Diagnosis. Report of a Task Force of the EULAR Standing Committee for international clinical studies including therapeutics (ESCISIT).
Ann Rheum Dis, 65 (2006), pp. 1301-1311
[9.]
H.R. Schumacher, W. Taylor, N. Joseph-Ridge, F. Perez-Ruiz, L.X. Chen, N. Schlesinger, et al.
Special Interest Group (SIG) on Outcome Evaluations in Gout. OMERACT 8.
J Rheumatol, 34 (2007), pp. 1381-1385
[10.]
B. Lumbreras, E. Pascual, J. Frasquet, J. Gonzalez-Salinas, E. Rodriguez, I. Hernandez-Aguado.
Analysis for crystals in synovial fluid: training of the analysts results in high consistency.
Ann Rheum Dis, 64 (2005), pp. 612-615
[11.]
N. Dalbeth.
Medidas de desenlace en los estudios sobre gota crónica: uricemia y medición de los tofos.
Reumatol Clin, 10 (2010), pp. 18-22
[12.]
F. Perez-Ruiz, S. Hernandez-Baldizon, A. Herrero-Beites, M.A. Gonzalez-Gay.
Risk factors associated to renal lithiasis during uricosuric treatment of hyperuricemia of gout.
Arthritis Care Res (Hoboken), 62 (2010), pp. 1299-1305
[13.]
F. Perez Ruiz.
Tratamiento de la gota: reflexiones desde el estudio GEMA.
Reumatol Clin, 8 (2008), pp. 41-44
[14.]
F. Perez-Ruiz, F. Lioté.
Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?.
Arthritis Rheum, 57 (2007), pp. 1324-1328
[15.]
AEMyPS. Alopurinol. 2007; available from: http://sinaem4.agemed.es/consaem/especialidad.do?metodo=verFichaHtml&codigo=56360&fichaCompleta=S.
Copyright © 2011. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
